ZNTLZentalis Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Zentalis Pharmaceuticals, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZNTLEsta | $218M#8 | — | 1.5x#9 | — | -100.0%#8 | 17.4%#8 | — | -95.4%#13 | — | — | 103.7%#4 | — |
| ALXO | $237M#2 | — | 1.7x#12 | — | — | 24.6%#7 | — | -74.7%#11 | -84.4%#3 | — | 58.1%#5 | — |
| WHWK | $236M#3 | — | 1.3x#7 | 33.1x#6 | -72.5%#6 | 67.7%#5 | -1601.1%#7 | -11.3%#7 | — | — | 107.8%#2 | — |
| RNAC | $233M#4 | — | — | 583.2x#8 | -99.0%#7 | -68.3%#14 | -35851.3%#8 | — | — | — | -25.3%#11 | — |
| NATR | $231M#5 | 13.1x#2 | 1.7x#10 | 0.5x#2 | 5.7%#4 | 153.7%#3 | 5.2%#4 | 14.3%#3 | — | 9#1 | -20.2%#10 | — |
| KROS | $224M#6 | — | 0.9x#3 | 0.9x#3 | 6775.0%#1 | 146.4%#4 | 27.7%#1 | 33.2%#1 | — | — | -29.4%#12 | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| SIGA | $220M#7 | — | 1.3x#8 | 2.3x#4 | -31.8%#5 | -60.7%#13 | 25.1%#2 | 14.1%#4 | — | — | -58.7%#13 | 19.6%#1 |
| ELDN | $212M#9 | — | 6.4x#14 | — | — | -26.1%#12 | — | -138.2%#14 | — | — | 2.4%#8 | — |
| NKTX | $203M#10 | — | 0.8x#2 | — | — | 4.3%#10 | — | -42.0%#8 | — | — | 43.4%#6 | — |
| PEPG | $202M#11 | — | 1.7x#11 | — | — | 0.4%#11 | — | -75.0%#12 | — | — | 41.1%#7 | — |
| TNXP | $196M#12 | — | 0.9x#4 | 14.9x#5 | 29.8%#2 | 4.6%#9 | -959.1%#6 | -55.8%#10 | -234.8%#4 | — | -59.6%#14 | — |
| ORMP | $194M#13 | 1.1x#1 | 1.0x#5 | 96.8x#7 | — | 573.1%#2 | -754.4%#5 | 0.0%#5 | -4.4%#2 | — | 104.6%#3 | — |
| CNTN | $185M#15 | — | 0.4x#1 | — | — | -194.5%#15 | — | -7.9%#6 | — | — | -12.6%#9 | — |
| ANTX | $187M#14 | — | 2.5x#13 | — | — | 31.5%#6 | — | -46.3%#9 | — | — | 254.5%#1 | — |
| ORGO | $177M#16 | — | 1.2x#6 | 0.3x#1 | 17.0%#3 | 4011.1%#1 | 7.9%#3 | 25.0%#2 | 23.2%#1 | — | -71.1%#15 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice